Status:

COMPLETED

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Disorder Related to Renal Transplantation

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this clinical research study is to learn if belatacept (BMS-224818) is expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based immunosuppressive regim...

Eligibility Criteria

Inclusion

  • Living or deceased donor renal allograft
  • Men and women, 18 to 70 years old
  • Subjects who have received a de novo kidney transplant, who have completed the initial study treatment through Month 12, and are willing to sign informed consent will be eligible to continue into the long term extension phase

Exclusion

  • Pregnant or breastfeeding women
  • Epstein Barr Virus (EBV) negative serology
  • First time renal transplant with panel reactive antibody (PRA) ≥ 50% or retransplantation with PRA \> 30%
  • Graft loss due to AR
  • Positive T-cell or B-cell crossmatch
  • Recipients/donors with HIV or hepatitis B/C
  • Active tuberculosis (TB)
  • Immunosuppressive therapy within 1 year of enrollment
  • UNOS ECD organs will be excluded
  • Body mass index (BMI) \> 35 kg/m²
  • Subjects who have developed any malignancy (other than non-melanoma skin cancer) or other medical condition that, in the investigator's opinion, should not be treated with an experimental immunosuppressive drug like belatacept

Key Trial Info

Start Date :

July 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

93 Patients enrolled

Trial Details

Trial ID

NCT00455013

Start Date

July 1 2007

End Date

August 1 2012

Last Update

June 9 2014

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Ucsf

San Francisco, California, United States, 94143

2

Denver Nephrology, Pc

Denver, Colorado, United States, 80218

3

University Of Colorado Health Sciences Center

Denver, Colorado, United States, 80262

4

Medical College Of Georgia

Augusta, Georgia, United States, 30912

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation | DecenTrialz